On July 24-28, 2016, the World Federation of Hemophilia World Congress A was held in Orlando (FL, USA).
The results of the analysis of patients with FXIII deficiency enrolled in PRO-RBDD project were submitted and accepted as oral communication: “Minimal residual FXIII coagulant activity to prevent spontaneous major bleeding”. You can find the abstract text at